Who
Corinne Le Goff
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Viatris; Director, Longboard Pharmaceuticals; President and CEO, Imunon; Chief Commercial Officer, Moderna.
In numbers
- Trades disclosed
- 69
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $72K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 1 Feb 2021
- Last trade
- 15 Apr 2026
- Last filed
- 16 Apr 2026
Companies traded
Activity over time
1 Sep 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Apr 2026filed 16 Apr 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —39,344 at $0.00 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $242K17,450 at $13.86 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —3,644 at $0.00 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —39,344 at $0.00 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,643.83 at $0.00 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $22K1,617 at $13.86 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —39,344 at $0.00 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,643.834 at $0.00 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —39,344 at $0.00 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $242K17,450 at $13.86 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —3,644 at $0.00 | filing |
| 15 Apr 2026filed 16 Apr 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $22K1,617 at $13.86 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —44,165 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $277K19,588 at $14.16 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —2,193 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —44,165 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,192.01 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —88,984 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $14K973 at $14.16 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —44,165 at $0.00 | filing |
News
Viatris' Dividend Has Room to Grow, but Will Management Deliver?VTRS · insidermonkey.com · 19 Oct 2026Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of PresbyopiaVTRS · prnewswire.com · 16 Oct 2026
0 headlines in the last 90 days name Corinne Le Goff; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.